EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 161 filers reported holding EAGLE PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $202 | -4.3% | 7,130 | -1.7% | 0.00% | -33.3% |
| Q4 2022 | $211 | -99.9% | 7,251 | -1.5% | 0.00% | 0.0% |
| Q3 2022 | $194,000 | -48.3% | 7,358 | -12.9% | 0.00% | -40.0% |
| Q2 2022 | $375,000 | -4.1% | 8,449 | +6.8% | 0.01% | +25.0% |
| Q1 2022 | $391,000 | -4.4% | 7,909 | -1.7% | 0.00% | 0.0% |
| Q4 2021 | $409,000 | -12.8% | 8,049 | -4.3% | 0.00% | -20.0% |
| Q3 2021 | $469,000 | +35.9% | 8,409 | +4.1% | 0.01% | +66.7% |
| Q2 2021 | $345,000 | +5.5% | 8,074 | +2.8% | 0.00% | -25.0% |
| Q1 2021 | $327,000 | -22.1% | 7,854 | -13.0% | 0.00% | -20.0% |
| Q4 2020 | $420,000 | -12.7% | 9,024 | -20.3% | 0.01% | -16.7% |
| Q3 2020 | $481,000 | +7.8% | 11,324 | +21.7% | 0.01% | 0.0% |
| Q2 2020 | $446,000 | +3.5% | 9,304 | -0.9% | 0.01% | -14.3% |
| Q1 2020 | $431,000 | -5.9% | 9,384 | +22.8% | 0.01% | +16.7% |
| Q4 2019 | $458,000 | +4.3% | 7,639 | -1.7% | 0.01% | 0.0% |
| Q3 2019 | $439,000 | +125.1% | 7,771 | +121.6% | 0.01% | +100.0% |
| Q2 2019 | $195,000 | +11.4% | 3,507 | +0.9% | 0.00% | 0.0% |
| Q1 2019 | $175,000 | +17.4% | 3,477 | -6.5% | 0.00% | 0.0% |
| Q4 2018 | $149,000 | -40.4% | 3,717 | +3.0% | 0.00% | -25.0% |
| Q3 2018 | $250,000 | +22.5% | 3,607 | +33.5% | 0.00% | 0.0% |
| Q2 2018 | $204,000 | +43.7% | 2,702 | 0.0% | 0.00% | +33.3% |
| Q1 2018 | $142,000 | +57.8% | 2,702 | +59.7% | 0.00% | +50.0% |
| Q4 2017 | $90,000 | -10.0% | 1,692 | 0.0% | 0.00% | -60.0% |
| Q3 2017 | $100,000 | -20.0% | 1,692 | +6.3% | 0.01% | -44.4% |
| Q2 2017 | $125,000 | +71.2% | 1,592 | +78.9% | 0.01% | +80.0% |
| Q1 2017 | $73,000 | +7.4% | 890 | +3.5% | 0.01% | -28.6% |
| Q4 2016 | $68,000 | – | 860 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 3,652,284 | $302,920,000 | 91.10% |
| Hudson Executive Capital LP | 1,901,200 | $157,686,000 | 21.62% |
| JW Asset Management, LLC | 525,755 | $43,606,000 | 9.08% |
| Cormorant Asset Management, LP | 200,000 | $16,588,000 | 2.41% |
| Park West Asset Management LLC | 488,128 | $40,485,000 | 2.36% |
| Opaleye Management Inc. | 50,000 | $4,147,000 | 2.06% |
| Ranger Investment Management | 283,954 | $23,551,000 | 1.71% |
| Pier Capital, LLC | 74,732 | $6,198,000 | 1.06% |
| Bellevue Group AG | 67,700 | $5,615,000 | 0.75% |
| Orbimed Advisors | 671,000 | $55,653,000 | 0.63% |